Park, J. Y. & Wu, L. T. Prevalence, causes, perceived results, and correlates of medical marijuana use: A evaluation. Drug. Alcohol. Rely. 177, 1–13. https://doi.org/10.1016/j.drugalcdep.2017.03.009 (2017).
Epidyolex|European Medicines Company. https://www.ema.europa.eu/en/medicines/human/EPAR/epidyolex (2021).
Anwar, A., Saleem, S., Patel, U. Ok., Arumaithurai, Ok. & Malik, P. Dravet syndrome: An summary. Cureus https://doi.org/10.7759/cureus.5006 (2019).
Asadi-Pooya, A. A. Lennox-Gastaut syndrome: A complete evaluation. Neurol. Sci. 393(39), 403–414 (2017).
Swaminath, A. et al. The position of hashish within the administration of inflammatory bowel illness: a evaluation of scientific, scientific, and regulatory informationcommissioned by the crohn’s and colitis basis. Inflamm. Bowel Dis. 25, 427–435. https://doi.org/10.1093/ibd/izy319 (2019).
Aran, A., Cassuto, H., Lubotzky, A., Wattad, N. & Hazan, E. Transient report: Cannabidiol-rich hashish in kids with autism spectrum dysfunction and extreme behavioral problems-a retrospective feasibility research. J. Autism Dev. Disord. 49, 1284–1288. https://doi.org/10.1007/s10803-018-3808-2 (2019).
Ben-Zeev, B. Medical hashish for intractable epilepsy in childhood: A evaluation. Rambam Maimonides Med. J. 11, e0004. https://doi.org/10.5041/RMMJ.10387 (2020).
Tramèr, M. R. et al. Cannabinoids for management of chemotherapy induced nausea and vomiting: Quantitative systematic evaluation. Br. Med. J. 323, 16–21. https://doi.org/10.1136/bmj.323.7303.16 (2001).
Pacher, P., Kogan, N. M. & Mechoulam, R. Past THC and endocannabinoids. Annu. Rev. Pharmacol. Toxicol. 60, 637–659. https://doi.org/10.1146/annurev-pharmtox-010818-021441 (2020).
Skrypek, M. M., Bostrom, B. C. & Bendel, A. E. Medical hashish certification in a big pediatric oncology middle. Kids 6, 79. https://doi.org/10.3390/children6060079 (2019).
Nationwide Academies of Sciences, Engineering, and Drugs. The Well being Results of Hashish and Cannabinoids: The Present State of Proof and Suggestions for Analysis. 58,91,97,245 (Washington, DC: The Nationwide Academies Press. 2017), DOI: https://doi.org/10.17226/24625.
Bourgeois, F. T. et al. Pediatric versus grownup drug trials for circumstances with excessive pediatric illness burden. Pediatrics 130, 285–292. https://doi.org/10.1542/peds.2012-0139 (2012).
Mueller, B. U. et al. Rules of pediatric affected person security: Lowering hurt as a result of medical care. Pediatrics 143, 2. https://doi.org/10.1542/peds.2012-0139 (2019).
Volkow, N. D., Baler, R. D., Compton, W. M. & Weiss, S. R. B. Hostile well being results of marijuana use. N. Engl. J. Med. 370, 2219–2227. https://doi.org/10.1056/NEJMra1402309 (2014).
Kelly, B. F. & Nappe, T. M. Cannabinoid Toxicity. Treasure Island (FL): StatPearls (StatPearls Publishing, 2019). PMID: 29489164.
Martín-Gómez, A., Palacios-Gómez, M. E. & García-Marcos, S. A. Extreme intradialytic hypoglycemia related to marijuana use. Nefrologia. 35, 328–329. https://doi.org/10.1016/j.nefroe.2015.02.001 (2015).
Naji, L. et al. The affiliation between hashish use and suicidal habits in sufferers with psychiatric issues: an evaluation of intercourse variations. Biol. Intercourse Differ. 9, 22. https://doi.org/10.1186/s13293-018-0182-x (2018).
Ragazzi, T. C. C., Shuhama, R., Menezes, P. R. & Del-Ben, C. M. Hashish use as a threat issue for psychotic-like experiences: A scientific evaluation of non-clinical populations evaluated with the Group Evaluation of Psychic Experiences. Early Interv. Psychiatry 12, 1013–1023. https://doi.org/10.1111/eip.12693 (2018).
Lev-Ran, S. et al. The affiliation between hashish use and melancholy: A scientific evaluation and meta-analysis of longitudinal research. Psychol. Med. 44, 797–810. https://doi.org/10.1017/S0033291713001438 (2014).
van Gastel, W. A. et al. Change in hashish use within the common inhabitants: A longitudinal research on the influence on psychotic experiences. Schizophr. Res. 157, 266–270. https://doi.org/10.1016/J.SCHRES.2014.04.023 (2014).
Appelboam, A. & Oades, P. J. Coma as a result of hashish toxicity in an toddler. Eur. J. Emerg. Med. 13, 177–179. https://doi.org/10.1097/01.mej.0000194405.38206.f2 (2006).
Carstairs, S. D., Fujinaka, M. Ok., Keeney, G. E. & Ly, B. T. Extended coma in a toddler as a result of cannabis ingestion with quantitation of THC metabolites in urine. J. Emerg. Med. 41, 3. https://doi.org/10.1016/j.jemermed.2010.05.032 (2011).
Bonkowsky, J. L., Sarco, D. & Pomeroy, S. L. Ataxia and shaking in a 2-year-old lady: Acute marijuana intoxication presenting as seizure. Pediatr. Emerg. Care. 21, 527–528. https://doi.org/10.1097/01.pec.0000173349.38024.33 (2005).
Richards, J. R., Smith, N. E. & Moulin, A. Ok. Unintentional hashish ingestion in kids: A scientific evaluation. J. Pediatr. 190, 142–152. https://doi.org/10.1016/j.jpeds.2017.07.005 (2017).
Corsi, D. J. et al. Maternal hashish use in being pregnant and little one neurodevelopmental outcomes. Nat. Med. 26, 1536–1540. https://doi.org/10.1038/s41591-020-1002-5 (2020).
Sadhana, D., Kathleen, M. & Jonathan, D. Ok. Marijuana and the pediatric inhabitants. Pediatrics https://doi.org/10.1542/peds.2019-2629 (2020).
Wong, S. S. & Wilens, T. E. Medical cannabinoids in kids and adolescents: A scientific evaluation. Pediatrics 140, 5. https://doi.org/10.1542/peds.2017-1818 (2017).
Devinsky, O. et al. Trial of cannabidiol for drug-resistant seizures within the dravet syndrome. N. Engl. J. Med. 376, 2011–2020. https://doi.org/10.1056/NEJMoa1611618 (2017).
Porcari, G. S., Fu, C., Doll, E. D., Carter, E. G. & Carson, R. P. Efficacy of artisanal preparations of cannabidiol for the therapy of epilepsy: Sensible experiences in a tertiary medical middle. Epilepsy Behav. 80, 240–246. https://doi.org/10.1016/j.yebeh.2018.01.026 (2018).
Devinsky, O. et al. Impact of cannabidiol on drop seizures within the lennox-gastaut syndrome. N. Engl. J. Med. 378, 1888–1897. https://doi.org/10.1056/NEJMoa1714631 (2018).
Lattanzi, S. et al. Efficacy and security of cannabidiol in epilepsy: A scientific evaluation and meta-analysis. Medication 78, 1791–1804. https://doi.org/10.1007/s40265-018-0992-5 (2018).
de Carvalho, R. R., Almeida, Ok. J., da Silva, L. L., de Melo Mendes, C. M. & Bor-Seng-Shu, E. Efficacy and antagonistic occasion profile of cannabidiol and medicinal hashish for treatment-resistant epilepsy: Systematic evaluation and meta-analysis. Epilepsy Behav. 102, 106635. https://doi.org/10.1016/j.yebeh.2019.106635 (2020).
Liberati, A. et al. The PRISMA assertion for reporting systematic opinions and meta-analyses of research that consider healthcare interventions: clarification and elaboration. BMJ 339, b2700. https://doi.org/10.1136/bmj.b2700 (2009).
Ouzzani, M., Hammady, H., Fedorowicz, Z. & Elmagarmid, A. Rayyan-a internet and cell app for systematic opinions. Syst. Rev. 5(210), 1. https://doi.org/10.1186/s13643-016-0384-4 (2016).
Sterne, J. A. et al. ROBINS-I: A software for assessing threat of bias in non-randomised research of interventions. BMJ 355, i4919. https://doi.org/10.1136/bmj.i4919 (2016).
Higgins, J. P. T. et al. The Cochrane Collaboration’s software for assessing threat of bias in randomised trials. BMJ 343, i7829. https://doi.org/10.1136/bmj.d5928 (2011).
Busner, J. & Targum, S. D. The scientific international impressions scale: Making use of a analysis software in scientific observe. Psychiat. Edgmont 4(7), 28–37 (2007).
European Medicines Company. Vital medical occasion phrases record (MedDRA model 23.0, up to date). https://www.ema.europa.eu/en/documents/other/important-medical-event-terms-list-version-meddra-version-221_en.xls (2020).
Viechtbauer, W. Conducting meta-analyses in R with the metafor. J. Stat. Softw. 36, 1–48. https://doi.org/10.18637/jss.v036.i03 (2010).
Balduzzi, S., Rücker, G. & Schwarzer, G. How you can carry out a meta-analysis with R: A sensible tutorial. Evid. Based mostly. Ment. Well being 22, 153–160. https://doi.org/10.1136/ebmental-2019-300117 (2019).
Rücker, G., Krahn, U., König, J., Efthimiou, O. & Schwarzer, G. Bundle ‘netmeta’ title community meta-analysis utilizing frequentist strategies. Epidemiol. Well being https://doi.org/10.1007/978-3-319-21416 (2020).
McGrath, S., Zhao, X., Steele, R. & Benedetti, A. Bundle ‘metamedian’ Title Meta-Evaluation of Medians. (2020). https://doi.org/10.1002/sim.8013.
Copenhagen Trial Unit. Trial Sequential Evaluation Viewer. (2016).
Wetterslev, J., Thorlund, Ok., Brok, J. & Gluud, C. Estimating required data dimension by quantifying variety in random-effects mannequin meta-analyses. BMC Med. Res. Methodol. 91(9), 1–12. https://doi.org/10.1186/1471-2288-9-86 (2009).
Borenstein, M., Hedges, L., Higgins, J., Rothstein, H. & Biostat Englewood, N.J. Complete Meta-Evaluation 3. (2013).
Dean, A.G., Sullivan, Ok.M., Soe, M.M. OpenEpi: Open supply epidemiologic statistics for public well being, Model. www.OpenEpi.com, up to date 2013/04/06, accessed 2021/10/16.
Web page, M. J. et al. Epidemiology and reporting traits of systematic opinions of biomedical analysis: A cross-sectional research. PLOS Med. 13, e1002028. https://doi.org/10.1371/journal.pmed.1002028 (2016).
Chan, S. G., Correia, A. J. & MecLeod, M. S. Nabilone versus prochlorperazine for management of most cancers chemotherapy-induced emesis in kids: A double-blind, crossover trial. Pediatrics 79(6), 946–952 (1987).
Dalzell, A. M., Bartlett, H. & Lilleyman, J. S. Nabilone: Another antiemetic for most cancers chemotherapy. Arch. Dis. Youngster. 61, 502–505. https://doi.org/10.1136/adc.61.5.502 (1986).
Miller, I. et al. Dose-ranging impact of adjunctive oral cannabidiol vs placebo on convulsive seizure frequency in dravet syndrome: A randomized scientific trial. JAMA Neurol. 77, 613–621. https://doi.org/10.1001/jamaneurol.2020.0073 (2020).
Fairhurst, C., Kumar, R., Checketts, D., Tayo, B. & Turner, S. Efficacy and security of nabiximols cannabinoid drugs for paediatric spasticity in cerebral palsy or traumatic mind harm: a randomized managed trial. Dev. Med. Youngster Neurol. 62, 1031–1039. https://doi.org/10.1111/dmcn.14548 (2020).
Efron, D. et al. A pilot randomised placebo-controlled trial of cannabidiol to cut back extreme behavioural issues in kids and adolescents with mental incapacity. Br. J. Clin. Pharmacol. 87, 436–446. https://doi.org/10.1111/bcp.14399 (2021).
Aran, A. et al. Cannabinoid therapy for autism: A proof-of-concept randomized trial. Mol. Autism 12, 1–11. https://doi.org/10.1186/S13229-021-00420-2 (2021).
Devinsky, O. et al. Randomized, dose-ranging security trial of cannabidiol in Dravet syndrome. Neurology 90, e1204–e1211. https://doi.org/10.1212/WNL.0000000000005254 (2018).
Chesney, E. et al. Hostile results of cannabidiol: A scientific evaluation and meta-analysis of randomized scientific trials. Neuropsychopharmacology 45, 1799–1806. https://doi.org/10.1038/s41386-020-0667-2 (2020).
Malyshevskaya, O. et al. Pure (∆ 9 -THC) and artificial (JWH-018) cannabinoids induce seizures by performing by the cannabinoid CB 1 receptor. Sci. Rep. 2017(7), 1–8. https://doi.org/10.1038/s41598-017-10447-2 (2017).
FDA Approves First Drug Comprised of an Lively Ingredient Derived from Marijuana to Deal with Uncommon, Extreme Types of Epilepsy. FDA https://www.fda.gov/news-events/press-announcements/fda-approves-first-drug-comprised-active-ingredient-derived-marijuana-treat-rare-severe-forms (2018).
Ruggiero, A. et al. Acute chemotherapy-induced nausea and vomiting in kids with most cancers: Nonetheless ready for a standard consensus on therapy. J. Int. Med. Res. 46, 2149–2156. https://doi.org/10.1177/0300060518765324 (2018).
NICE. Hashish-based medicinal merchandise: [A] Proof evaluation for intractable nausea and vomiting NICE guideline NG144 Proof evaluation underpinning suggestions 1.1.1 and 1.1.2 within the NICE guideline. (2019).
Huestis, M. A. et al. Cannabidiol antagonistic results and toxicity. Curr. Neuropharmacol. 17, 974–989. https://doi.org/10.2174/1570159×17666190603171901 (2019).
Stockings, E. et al. Proof for hashish and cannabinoids for epilepsy: a scientific evaluation of managed and observational proof. J. Neurol. Neurosurg. Psychiat. 89, 741–753. https://doi.org/10.1136/JNNP-2017-317168 (2018).
Wiley, J. L. et al. CB1 cannabinoid receptor-mediated modulation of meals consumption in mice. Br. J. Pharmacol. 145, 293. https://doi.org/10.1038/SJ.BJP.0706157 (2005).
Jankowska, B. I., Jankowski, M. M. & Swiergiel, A. H. Cannabidiol decreases physique weight achieve in rats: involvement of CB2 receptors. Neurosci. Lett. 490, 82–84. https://doi.org/10.1016/J.NEULET.2010.12.031 (2011).
Skluzacek, J. V., Watts, Ok. P., Parsy, O., Wical, B. & Camfield, P. Dravet syndrome and father or mother associations: The IDEA League expertise with comorbid circumstances, mortality, administration, adaptation, and grief. Epilepsia 52, 95–101. https://doi.org/10.1111/j.1528-1167.2011.03012.x (2011).
Bandini, L. G. et al. Adjustments in meals selectivity in kids with autism spectrum dysfunction. J. Autism Dev. Disord. 47, 439–446. https://doi.org/10.1007/s10803-016-2963-6 (2017).
Di Marzo, V. & Piscitelli, F. The endocannabinoid system and its modulation by phytocannabinoids. Neurotherapeutics 12, 692. https://doi.org/10.1007/s13311-015-0374-6 (2015).
Zou, S. & Kumar, U. Cannabinoid receptors and the endocannabinoid system: Signaling and performance within the central nervous system. Int. J. Mol. Sci. 1, 9. https://doi.org/10.3390/ijms19030833 (2018).
Netzahualcoyotzi, C., Rodríguez-Serrano, L. M., Chávez-Hernández, M. E. & Buenrostro-Jáuregui, M. H. Early consumption of cannabinoids: From grownup neurogenesis to habits. Int. J. Mol. Sci. 22, 7450. https://doi.org/10.3390/ijms22147450 (2021).
Solowij, N. et al. Therapeutic results of extended cannabidiol therapy on psychological signs and cognitive operate in common hashish customers: A practical open-label scientific trial. Hashish Cannabinoid. Res. 3, 21–34. https://doi.org/10.1089/can.2017.004 (2018).
Osborne, A. L., Solowij, N. & Weston-Inexperienced, Ok. A scientific evaluation of the impact of cannabidiol on cognitive operate: Relevance to schizophrenia. Neurosci. Biobehav. Rev. 72, 310–324. https://doi.org/10.1016/j.neubiorev.2016.11.012 (2017).
Sidik, Ok. & Jonkman, J. N. A comparability of heterogeneity variance estimators in combining outcomes of research. Stat. Med. 26, 1964–1981 (2007).
